Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 1Neoplasms 1

Interventions

tislelizumab 3Paclitaxel 3Nivolumab 3pembrolizumab 2atezolizumab 2Docetaxel 2ulocuplumab 1tazemetostat 1tazarotene 1seviteronel 1rucaparib 1romiplostim 1phosphorylethanolamine 1pertuzumab 1neratinib 1magrolimab 1fluzoparib 1fludarabine 1epacadostat 1durvalumab 1camrelizumab 1Trastuzumab 1Sunitinib 1Poly(ADP-ribose) Polymerase Inhibitors 1LY2510924 1EC145 1Cyclophosphamide 1CH5183284 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Solid Tumor × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
31 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡